 Eligible patients will be randomized into two groups: denosumab versus placebo. Each patient will attend a total of 8 scheduled visits, which will be completed over a period of 24 months - 15days from screening visit to end of study inclusion, 10 days, and 3, 6, 12, 15, 18, 24 months. 